However, the cohort shifting from anti-PD-(L)1 to anti-CTLA-4in this study mainly included patients with melanoma, so caution should be taken for othertypes of cancer when making the decision to switch to anti-CTLA-4 monotherapy forrechallenge. Here, CTLA4 is linked to melanoma.